The Antibodies Contract Manufacturing Market size is projected to reach USD 38.30 Bn by 2031

A newly published report by Coherent Market Insights reveals a sustainable growth opportunity in the antibodies contract manufacturing market. Coherent Market Insights’ analyst projected the antibodies contract manufacturing market to be valued at USD 38.30 Bn by 2031. It is expected to exhibit a CAGR of 10% during the forecast period from 2024 to 2031.

Increasing demand for monoclonal antibodies and rising R&D investment in the biopharmaceutical sector drives market growth. Monoclonal antibodies have wide applications in various therapeutic areas such as cancer, cardiovascular, and other chronic diseases.

Moreover, the increasing complexities in developing innovative antibody treatments have compelled biopharmaceutical companies to outsource their antibody manufacturing processes to contract manufacturers. This is expected to support the market growth over the forecast period.

Key market trends include Advent of biosimilars: The expiration of some big antibody patents in the coming years is anticipated to boost the demand for biosimilars or generic versions of innovator antibodies drugs. The contract manufacturing organizations are strengthening their capabilities and services to facilitate the development and manufacturing of biosimilar antibodies.

Rising adoption of pre-filled syringes: Pre-filled syringes offer advantages such as controlled dose dispensing and easy self-administration as compared to conventional vials and bottles. The pre-filled syringes also help in preventing dosing errors and needless sticks. Many biopharmaceutical companies are collaborating with contract manufacturers for developing pre-filled syringes for monoclonal antibody drugs.

Antibodies Contract Manufacturing Market Opportunities: The microbial systems segment currently holds the largest share of the market, accounting for around 40% share in 2023. E. coli and yeast cells are commonly used microbial systems for the production of monoclonal and polyclonal antibodies. Their advantages such as ease of fermentation process and cost-effective production are driving their demand.

The mammalian cells segment is expected to witness the highest growth during the forecast period. Attributes such as ability to produce highly functional antibodies similar to human antibodies are increasing the preference for mammalian cells among biopharmaceutical companies. Within the segment, Chinese hamster ovary (CHO) cells are dominating owing to their high production capacity.

Key Market Takeaways: The antibodies contract manufacturing market is anticipated to witness a CAGR of 10% during the forecast period 2024-2031. This is owing to rapid approvals and launch of monoclonal antibody drugs and growing reliance on contract manufacturing organizations for drug development.

On the basis of source, microbial systems segment is expected to hold a dominant position, accounting for around 40% of the market share in 2023. This is due to their cost-effective production process.

On the basis of product type, monoclonal antibodies segment is projected to dominate over the forecast period. This is driven by the high demand for monoclonal antibody drugs for treating various diseases including cancer.

On the basis of region, North America is expected to hold a dominant position over the forecast period. This is owing to presence of majority of contract manufacturing companies and global biopharmaceutical players in the region.

Competitor Insights: Key players operating in the antibodies contract manufacturing market include Lonza Group, WuXi Biologics, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Rentschler Biopharma SE, Charles River Laboratories, Samsung Biologics, AbbVie Contract Manufacturing, Merck KGaA, BioNTech SE, Amgen, Inc., Genentech, Inc., Takeda Pharmaceutical Company, Celerion, and Avid Bioservices, Inc.

Recent Developments: In October 2024 a strategic alliance was established between the biopharmaceutical companies GBI Biomanufacturing and Allterum Therapeutics to produce 4A10, Allterum’s lead monoclonal antibody that targets CD127, for use in clinical trials to treat a variety of malignancies. More information in full report